Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model.
about
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized miceLipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectivesNew generation humanized mice for virus research: comparative aspects and future prospectsGene therapy strategies for HIV/AIDS: preclinical modeling in humanized miceCombined antiviral activity of interferon-α and RNA interference directed against hepatitis C without affecting vector delivery and gene silencingExcision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinaseCD25 preselective anti-HIV vectors for improved HIV gene therapy.Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy.Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse modelA highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.Humanized Rag1-/- γc-/- mice support multilineage hematopoiesis and are susceptible to HIV-1 infection via systemic and vaginal routesHumanized mouse models to study human diseasesIn silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.Silencing of HIV-1 gag gene from epidemic strains among men who have sex with men (MSM) in Tianjin, China by a broad-spectrum short hairpin RNA.Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis.An RNAi in silico approach to find an optimal shRNA cocktail against HIV-1.The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment.RNA interference approaches for treatment of HIV-1 infectionEfficient inhibition of HIV-1 replication by an artificial polycistronic miRNA construct.Efficient inhibition of human immunodeficiency virus replication using novel modified microRNA-30a targeting 3'-untranslated region transcripts.ESF-EMBO symposium: antiviral applications of RNA interference.Novel humanized murine models for HIV research.Humanized mouse models of HIV infectionSpecific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization.Selection of RNAi-based inhibitors for anti-HIV gene therapyPreclinical in vivo evaluation of the safety of a multi-shRNA-based gene therapy against HIV-1The utilization of humanized mouse models for the study of human retroviral infections.Towards a genetic AIDS vaccine.Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing.RNA-interference-based gene therapy approaches to HIV type-1 treatment: tackling the hurdles from bench to bedside.The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS.HIV-1 immunopathogenesis in humanized mouse models.Possible applications for replicating HIV 1 vectorsRNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside.Using TRIM5α as an HIV therapeutic: the alpha gene?Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy ApproachThe impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy.The therapeutic landscape of HIV-1 via genome editingCombinatorial RNAi against HIV-1 using extended short hairpin RNAs.Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform.
P2860
Q21090483-12DCA0CA-5659-4663-B188-09F4C04832DCQ26859021-36C026F7-BD18-426A-A245-D9D44B843817Q27014786-9689FFB9-9D70-4454-8129-EBB9614E89DDQ27022347-6CEC629E-77F6-409D-A4F6-1175906FB977Q27488834-66A3E43F-B0C8-4795-9A22-4FC80C6106B9Q28480614-A7456827-F09C-40A5-8537-0E5461123856Q33586299-11703364-92A2-4AA1-AFCB-94409A9F2B05Q33622741-21B87E2A-2FD6-4006-B220-D38A364F4AD8Q33676640-C9DD5F5A-D15B-4C94-BD39-3D42449B9F00Q33697336-D8E7EF61-1EE8-43AA-BCD4-851B2A730C3BQ33939330-716F1267-26AC-4C69-8416-478261D834A9Q33941638-07F03D07-C076-4961-B28A-0C5EAF081FA3Q34221633-822A4E83-8AE5-4864-8519-485C69D83C80Q34300106-46270CC6-4F38-4180-97B9-00324A8C5B52Q34474320-4589C761-B878-4B97-816D-4BA056454799Q34499103-6A150261-501C-4EFA-B8DF-EF848489DAA2Q35206268-CD96DECA-409B-41C4-BBCA-20977625AE64Q35652119-90122AD7-AA98-44D3-8C5F-4021593E2D49Q36156552-5AB99B5E-0903-4308-86BA-9C2462700F1FQ36824463-6E401FF5-90D4-415D-8A1B-BFBF13EEDEA8Q36916998-D6012B45-D38E-4565-9F96-F31E40549A4AQ37084504-822C33C0-4166-49B5-8E7B-974103F3A02DQ37089865-98890AE6-5778-4D18-A3B9-42CCAAF61E84Q37184391-1D93D045-3958-4FDE-9750-AE4B7484160FQ37195531-52F1E6AF-7629-4583-99CC-CC0623DBC7E0Q37256335-7FA4EA66-D9B0-40DB-811C-F70DB39AA801Q37346027-85266931-54CC-4892-86B6-3FA5B74045CCQ37397574-1C36B93A-2ADA-4E69-8E81-AC10655CDCE2Q37489352-62377B1F-FDA9-4809-813A-3D7669DECD7BQ37566034-8ADB6343-3128-41C3-B09F-99DD35B3F1A8Q37620810-435023B3-84E6-4789-8A54-57FA397DD0CEQ37676228-CAA0BDB6-4E96-4352-B3F6-EC348BA05226Q37768033-AAC46D8E-CCC4-41DA-9CAB-8372DCA74682Q37941651-C16EFDD9-76B0-4C53-934C-2085CB35A300Q38088406-DB0E1512-9416-4CC4-817C-1DF71C10E084Q38777152-5B6DEE42-F5DB-4DE6-B145-6DBFA6E9BB52Q39035301-F1EE9E61-0D64-4762-A60C-FEE8D50BDE05Q39153976-7C384213-3102-4A66-BB4C-F0ADC0A73A0EQ39502428-3075AA6B-7815-422A-A28C-40AA6CC54DEDQ39508077-3D0D4C6D-A6AC-41EA-9422-417AA6D328DB
P2860
Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Evaluation of safety and effic ...... (-/-)gammac(-/-)) mouse model.
@en
Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system
@nl
type
label
Evaluation of safety and effic ...... (-/-)gammac(-/-)) mouse model.
@en
Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system
@nl
prefLabel
Evaluation of safety and effic ...... (-/-)gammac(-/-)) mouse model.
@en
Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system
@nl
P2093
P2860
P356
P1433
P1476
Evaluation of safety and effic ...... (-/-)gammac(-/-)) mouse model.
@en
P2093
B Berkhout
K J von Eije
M Centlivre
O ter Brake
P2860
P2888
P304
P356
10.1038/GT.2008.124
P577
2008-07-31T00:00:00Z
P5875
P6179
1000455705